Expression of the von hippel-lindau tumor suppressor gene in nonneoplastic and neoplastic lesions of the thyroid

Endocrine Pathology

Volumn 11, Issue 2, 2000, Pages 145-155

  Hinze, Raoul ^a   Boltze, Carsten ^a   Meye, Axel ^a   Holzhausen, Hans Jürgen ^a   Dralle, Henning ^a   Rath, Friedrich Wilhelm ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Angiogenesis; Thyroid gland; Thyroid neoplasm; Vascular endothelial growth factor; Von Hippel Lindau tumor suppressor gene

Indexed keywords

CELL MARKER; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID ADENOMA; THYROID FOLLICLE; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 0033856270     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/ep:11:2:145     Document Type: Article

References (37)

1. 1. Lindor NM, Green MH. The concise handbook of family cancer syndromes. J Natl Cancer Inst 90:1039-1071, 1998.
2. 2. Kaelin WG, Maher ER. The VHL tumor-suppressor gene paradigm. Trends Genet 14:423-426, 1998.
3. 3. Webster AR, Richards FM, MacRonald FE, More AT, Maher ER. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genetics 63:1025-1035, 1998.
4. 4. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320, 1993.
5. 5. Los M, Jansen GH, Kaelin WG, Lips CJM, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 75:231-238, 1996.
6. 6. Corless CL, Kibel AS, Iliopoulos O, Kaelin WG. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 28:459-464, 1997.
7. 7. Kaelin WG, Iliopoulos O, Lonergan KM, Ohh M. Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med 243:535-539, 1998.
8. 8. Scheonfeld A, Davidowitz EJ, Burk JD. A second major native von Hippel-Lindau gene product, initiated from internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 95:8817-8822, 1998.
9. 9. Iliopoulos O, Ohh M, Kaelin WG. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 95:11,661-11,666, 1998.
10. 10. Sakashita N, Takeya M, Kishida T, Stackhouse TM, Zbar B, Takahashi K. Expression of von Hippel-Lindau protein in normal and pathological human tissues. Histochem J 31:133-144, 1999.
11. 11. Vortmeyer AO, Lubensky IA, Fogt F, Linehan WM, Khettry U, Zhuang Z. Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. Am J Pathol 151:951-956, 1997.
12. 12. Iliopoulos O, Kaelin WG. The molecular basis of von Hippel-Lindau disease. Mol Med 5:289-293, 1997.
13. 13. Sekido Y, Bader S, Latif F, Gnarra JR, Gazdar AF, Linehan WM, Zbar B, Lerman MI, Minna JD. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene 9:1599-1604, 1994.
14. 14. Kanno H, Shuin T, Kondo K, Yamamoto I, Ito S, Shinonaga M, Yoshida M, Yao M. Somatic mutations of the von Hippel-Lindau tumor suppressor gene and loss of heterozygosity on chromosome 3p in human glial tumors. Cancer Res 57:1035-1038, 1997.
15. 15. Fogt F, Vortmeyer AO, Stolte M, Mueller E, Mueller J, Noffsinger A, Poremba C, Zhuang Z. Loss of heterozygosity of the von Hippel Lindau gene locus in polypoid dysplasia but not flat dysplasia in ulcerative colitis or sporadic adenomas. Hum Pathol 29:961-964, 1998.
16. 16. Shiao YH, Rice JM, Anderson LM, Diwan BA, Hard GC. Von Hippel-Lindau gene mutations in N-nitrosodimethylamine-induced rat renal epithelial tumors. J Natl Cancer Inst 90:1720-1723, 1998.
17. 17. Mukhopadhyay D, Knebelmann B, Cohen HAT, Ananth S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17:5629-5639, 1997.
18. 18. Lazzereschi D, Mincione G, Coppa A, Ranieri A, Turco A, Baccheschi G, Pelicano S, Colletta G. Oncogenes and antioncogenes involved in human thyroid carcinogenesis. J Exp Clin Cancer Res 16:325-332, 1997.
19. 19. Rosai J, Carcangui ML, DeLellis RA. Poorly differentiated carcinoma. In: Rosai J, Sobin LH, eds. Tumors of the thyroid gland: atlas of tumor pathology. Third series, fascicle 5. Washington, DC: Armed Forces Institute of Pathology, 1992; 123-133.
20. 20. Remmele W, Hildebrand U, Hienz H, Klein PJ, Vierbuchen M, Behnken LJ, Heicke B, Scheidt E. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch 409:127-147, 1986.
21. 21. Fonseca E, Soares P, Rossi S, Sobrinho-Simoes M. Prognostic factors in thyroid carcinomas. Verh Dtsch Ges Pathol 81:82-96, 1997.
22. 22. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS. Von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 58:4957-4962, 1998.
23. 23. Gilcrease MZ, Schmidt L, Zbar B, Truong L, Rutledge M, Wheeler TM. Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. Hum Pathol 26:1341-1346, 1995.
24. 24. Lee JY, Dong SM, Park WS, Yoo NJ, Kim CS, Jang JJ, Chi JG, Zbar B, Lubensky IA, Linehan WM, Vortmeyer AO, Zhuang Z. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 58:504-508, 1998.
25. 25. Van der Harst E, de Krijger RR, Dinjens WN, Weeks LE, Bonjer HJ, Bruining HA, Lamberts SW, Koper JW. Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer 77:337-340, 1998.
26. 26. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149:2089-2094, 1996.
27. 27. Herman JG, Latif F, Wenig Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700-9704, 1994.
28. 28. Grebe SK, Mclver B, Hay ID Wu PS, Maciel LM, Drabkin HA, Goellner JR, Grant CS, Jenkins RB, Eberhardt NL. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol Metab 82:3684-3691, 1997.
29. 29. Flamme I, Krieg M, Plate KH. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/ HIF-2alpha. Am J Pathol 153:25-29, 1998.
30. 30. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56:2013-2016, 1996.
31. 31. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82:3741-3747, 1997.
32. 32. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G, Fusco A, Persico AG. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569-1579, 1995.
33. 33. Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, Galati MG, Mauriello V, Bruni P, Lago CT, Fusco A, Persico MG. Upregulation of the angiogenic factors PIGF, VEGF and their receptors (FIt-1, FIk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15:2687-2698, 1997.
34. 34. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 272:27,509-27,512, 1997.
35. 35. Knebelmann B, Ananth S, Cohen HT, Sukhatme VP. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 58:226-231, 1998.
36. 36. Los M, Zeamari S, Foekens JA, Gebbink MFBG, Voest EE. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res 59:4440-4445, 1999.
37. 37. Iwai K, Yamanaka K, Kamura T, Minota N, Conaway RC, Conaway JW, Klausner RD, Pause A. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. PNAS 96:12,436-12,441, 1999.